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Background
Influenza virus infections cause seasonal epidemics,
affecting millions of people worldwide. The World
Health Organization (WHO) estimates ∼300,000-500,000
deaths per year worldwide due to seasonal influenza and
more than $26.8-87.1 billion/year in healthcare costs in
the United States alone [1]. Influenza, a segmented RNA
virus achieves part of its ongoing virulence as a result of
its strikingly high mutation rate, typically reported for
Influenza A viruses of ~2 to 2.5 × 10−3mutations/site/
year. Thus, is the intense effort and energy devoted to
achieving effective long-term human and veterinarian
vaccines. Currently, licensed influenza vaccines are either
trivalent (three influenza strains) or quadrivalent (four
influenza strains), as either an injectable inactivated
whole virus (IIV) or a nasal spray live attenuated vaccine
(LAIV) [2]. Although efficacious, standard traditional
Influenza vaccine production is laborious, only moder-
ately high-throughput and requires physical plants hous-
ing and/or incubating millions of specific-pathogen-free
eggs. Research targeting alternate strategies has been pro-
digious, both at the preclinical and even Phase I clinical
level, and has investigated approaches such as split virion,
subunit, DNA, and viral vectored vaccines. Among the
recently-explored, more novel and potentially-promising
strategies has been recombinant particulate vaccines gen-
erally comprising virus-like particles or nanoparticles.
At the Vaccine Research Center (VRC), National Insti-
tute of Allergy and Infectious Disease (NIAID), National
Institutes of Health (NIH), fusion proteins of N-terminal
Influenza Hemagglutinin (HA) residues and C terminal
H. pylori ferritin residues have been conceived, designed,
expressed and determined to assemble into ferritin-like
cage nanoparticles termed hemagglutinin ferritin nano-
particles (HAF-NP). HAF-NP used as immunogens in
mouse immunization studies, elicited antibody titers
more than seven-fold higher and neutralizing antibody
titers with both extended breadth and greater potency
than the seasonal trivalent inactivated vaccine. Neutrali-
zation of H1N1 viruses extended to viruses from 1934 to
2007, and ferrets were protected by HAF-NP vaccination
against a heterologous virus [3].
Experimental approach
To enable HAF-NP to proceed to Phase I clinical trials,
the Vaccine Production Program (VPP), VRC has devel-
oped manufacturing processes amenable to GMP manu-
facture and FDA clearance for human clinical trials.
Among those processes, a transient gene expression
(TGE) system based on Polyethylenimine (PEI)-mediated
transfection for cell culture-based production of HAF
nanoparticles was developed. TGE was selected both
because of its short production time compared to stable
cell line generation and because of the specific require-
ments of vaccine manufacture. In rodent cell lines such
as Chinese Hamster Ovary, FDA requires that viral inac-
tivation or clearance of endogenous rodent viruses be
demonstrated, which may potentially compromise the
structural integrity of such an oligomeric 24-gon. To
address this problem for production, the human cell line
HEK293, harboring only the retroviruses endogenous to
those present in the clinical subjects, is commonly used as
a host cell. In addition, HEK293 cells have been shown to
have higher transfection efficiencies and are therefore typi-
cally used for TGE production. Thus, HEK293-based TGE
was selected as the method of choice to produce HAF. The
different HA-F constructs used were- H1 A/California/04/
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Results and conclusions
Transfection conditions, media, feed, process parameters
and scale up conditions were optimized to achieve a
high titer process. The effect of DNA to PEI ratio on
nanoparticle production was evaluated and the most
optimal DNA to PEI ratio was determined as 1:2 for
HAF nanoparticle production. In addition, a pDNA:PEI
ratio of 20 mg/L:40 mg/L was optimized for the transi-
ent transfection process. For the production medium
and feed, chemically-defined supplements were explored,
avoiding both animal-origin reagents and the subsequent
FDA requirement to demonstrate their elimination in
the final drug substance and the lot-to-lot variability some-
times present in chemically-complex, undefined media and
supplements. Data indicated that the chemically-defined
supplement Cell Boost 5 (CB 5 from Hyclone) added to the
basal production medium as well as in the production feed
significantly increased the productivity of nanoparticle pro-
duction. Process parameters and wave bag expression con-
ditions were optimized for a consistent process. 50L-scale
production of an influenza nanoparticle vaccine has been
successfully completed for Phase I clinical trials.
To summarize, a mammalian cell culture based process
was developed to ensure rapid, reliable and efficient produc-
tion of novel influenza nanoparticle vaccines. A transient
transfection platform process was optimized and scaled up
for 50L scale production of different HA-F nanoparticles.
Phase 1 clinical material has been successfully produced
and is in pre-clinical studies.
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Figure 1 A schematic representation of the transient transfection process is shown. The HEK 293 cells were grown in a 50L Single Use
Bioreactor (SUB). Cells were then washed and concentrated using a semi continuous centrifuge (kSep) and harvested into 3 Wave bags.
Transfection was carried out in the 3 Wave bags by adding pDNA and PEI. After 2 hours of incubation, production media was added. To
facilitate expression, Valproic acid (VPA) and production feed were added at 24 and 48 hours post-transfection, respectively and culture was
harvested at 96 hours post-transfection.
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